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Cyclic cage compounds have attracted much attention in pharmaceutical studies.  The 
lipophilic nature of these compounds plays an important role in facilitating the crossing of the 
cellular membranes, including the blood brain barrier (BBB) and the central nervous system 
(CNS).  Several adamantane and pentacyclo[5.4.0.02,6.03,10.05,9]undecane (PCU) derivatives 
have shown great potential as antiviral, antibacterial and neuroprotective compounds. 
The aim of this study includes the synthesis of hydantoin derivatives of adamantane and PCU 
as anticonvulsant compounds.  Fosphentoin sodium (Cerebyx) 48 is a commercial 
anticonvulsant drug.  Structurally, compound 51 and 52 are similar to Cerebyx 48, where the 
two phenyl groups have been replaced with PCU or adamantane skeleton respectively.  The 
cage skeleton should increase the lipophilic character of the drug whilst the phosphate group 
should retain the water solubility of the substrate.  The attempted synthesis of these 



























51 4852  
The PCU hydantoin is readily converted to the PCU amino acid.  The synthesis of the PCU 
amino acid 41 and its Fmoc derivative 106 is described in Chapter 3.   This compound was 
incorporated into small peptides, namely Ala-Ala-Ala-PCU-Ala-Ala-Ala-Fmoc and Ala-Val-
PCU-Ile for future testing as a potential anti-cancer agent.  NMR studies of these peptides are 
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This project involved the synthesis of cage amino acid derivatives having potential 
pharmaceutical applications.  The first part is the synthesis of cage hydantoins (precursor to 
the amino acid) as potential anti-epileptic drugs.  The second part involves the synthesis of a 
non-natural peptide with the aim of studying the 3D structure induced by the cage amino 
acid, the so called bio-active conformation.  The cage peptide is designed as a potential 
cancer agent, which will be investigated in subsequent studies.  The following is a a 
discussion of the background of various aspects related to this investigation.  First some 
pharmaceutical aspects of cage compounds will be presented.  
Cage compounds 
The chemistry of polycyclic “cage” compounds has been of great interest to synthetic 
chemists for over five decades.1-4  Pentacycloundecane (PCU) 1 polycyclic “cage” 
compounds possess unusual carbon-carbon bond lengths as well as C-C-C angles that deviate 
from 109.5o.  This is due to enormous ring strain caused by the cyclobutane ring.  With the 
exception of adamantane 2 and trishomocubane 3, most of the strained polycyclic “cage” 
compounds posses unusually high negative heats of decomposition and high positive energy 
of formation compared to other classes of saturated compounds.  This strain energy appears 
to express itself through unusual chemical reactivity.4  The following are structural examples 




3: Trishomocubane 4: Cubane  
The incorporation of cage compounds into medicinal drugs introduces a variety of advantages 
in terms of drug action and pharmacology.1  These advantages include:  
• The lipophilic nature of cage compounds makes them good candidates for drug 
delivery.  The bulky hydrocarbon framework serves as a transport aid in carrying 
drugs attached to them across the cellular membrane including the blood brain 
barrier (BBB) and the central nervous system (CNS).5-12  The first major 
breakthrough occurred with the discovery of amantadine 5 which was found to be 
an effective drug against Parkinson’s disease.  Amantadine also exhibits antiviral 
activity against the influenza A2 Asian virus.  Further derivatives of adamantine, 6 
and 7, have been reported to display anti-viral activity with less side effects.1  This 
has led to an evolution in drug discovery with the emergence of different classes 
of polycyclic “cage” based skeletons being synthesized and tested against a series 
of neurotic diseases.  A number of these compounds showed promising 
activities.1,7,12,13   
• Cage compounds covalently attached to pharmaceutically active molecules also 
reduce drug bio-degradation which helps to increase the half life of such 







5: Amantadine R1= H, R2=H







Figure 1: Examples of biological active polycyclic compounds  
Polycyclic compounds exhibit interesting structural properties e.g. the eleven carbon 
framework of PCU 1 and trishomocubane 3 have C2 and D3 symmetry respectively.





Chirality is one of the most important properties for compounds in asymmetric catalysis and 
pharmaceutical applications.  Despite the fact that PCU 1 is a meso compound all the methine 
groups become asymmetric when a chiral arm is attached to the cage skeleton.  A number of 
chiral PCU derivatives have been synthesised for several asymmetric applications.15-17  
These advantages of cage skeletons make it attractive to incorporate them into non-natural 
peptides.  Other advantages of the cage moiety will be presented in Chapter 3.   
Chapter 2 presents the synthesis of cage hydantoin derivatives as potential anti-convulsant 
derivatives.  The back ground of anti-convulsant agents will be presented there.  In addition, 
these hydantoin compounds can be hydrolysed to the corresponding cage amino acids.  The 
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latter will then be incorporated into non-natural peptides.  The following is an introduction to 
peptide chemistry.    
Peptide chemistry 
The peptide bond or peptide linkage is an amide bond formed by the interaction of an amino 
group and a carboxyl group of two amino acids.  This bond links together amino acids to 
yield a strand referred to as a peptide or protein.18,19  Of the 20 known natural amino acids 









10a: (R)-Cysteine 10b: (S)-Cysteine  
With an exception of a few cases (e.g. (R)-serine and (R)-aspartate in the brain tissue and (R)-
ornithine in gramicidin S), the 20 natural amino acids predominantly exist as (S)-
configuration.  In contrast to natural amino acids, the carbohydrate units are of opposite 
configuration.19   
X-ray studies of peptide bonds shows it contains unusual bond lengths and angles around the 
amide bond compared to the usual C-N bond.21  Protein and peptide backbone conformations 
are usually characterized by four torsion angles φ ψ, χ and ω (see Figure 2).  Where ω is 
normally 1800 with an exception of proline (ω = 00) where the amino acid side chain (R) 




                                                 

































Figure 2: Defining bond lengths and the torsion angles in the peptide backbone21   
These facts provide clear evidence that amide bonds possess partial double bond character, 
resulting from the delocalization of the nitrogen lone pair of electrons to the carbonyl group.  
This partial double bond in 12c restricts/hinders free rotation around the amide bond (Figure 
3).20,21  The backbone is trans across the amide bond (excluding proline) since steric 
















Figure 3: Delocalization in the peptide bond20 
Peptides exist in two major conformational forms, namely helical coils and β-sheets.  The 
nature and classification of helical coils will be discussed below.   
β-sheets form due to hydrogen bonding between two neighbouring polypeptides and are 
classified into two types (Figure 4).  
• Parallel β-sheets, the hydrogen bonding occurs between two peptides (C-terminal with 
C-terminal or N-terminal with N-terminal) align in parallel way. 
• Anti-parallel β-sheets, the hydrogen bonds take place between two anti-parallel 














































Figure 4: Formation of hydrogen bond in parallel and anti-parallel β-sheet plates21  
Peptides can also exhibit various types of turns or helical structures. 
Peptide turns 
The formation of a helical structure occurs when successive turns are present in a peptide or 
protein.  In most cases, hydrogen bonding is responsible for stabilizing particular peptide 
turns.  H-bonds occur between the α-amino groups and α-carboxyl groups in a nearby 
segment or residue.   
Depending on the number of the amino acid residues contributing to the specific turn, the 
type of turn is classified.  When three amino acids are involved in the hydrogen bonded turn, 
then the turn is called a γ-turn.  Similarly turns where four, five and six amino acids are 
involved are respectively called β, α and π-turns.21  Of these types of turns, β-turns represent 
by far the most important motives in terms of bio-active peptides.22  There are different types 
of β-turns which are classified according to the dihedral angles (ψ, φ) (see Figure 2) of the 
four amino acids (i, i+1, i+2, i+3).21  There are three criteria for defining β-turns:21,22  
• The decisive factor for the classification of β-turns is that the distance between the 
atoms Cα(i) and Cα (i+3) should be less than 7Å.  
• The torsion angle t between Cα (i), Cα (i+1), Cα (i+2) and Cα (i+3) ranges around 900≤ 
t ≤900. 
• The distance between the carbonyl group on amino acid (i) and the amide hydrogen 
on the amino acid (i+3) is less than 4 Å.   
β-turns can also be classified as different types based on the distinctive tetrahedral angles (ψ, 
φ) of the second and third amino acid residues [(i+1) and (i+2)].   
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Some amino acids are known to stabilize β-turns.  Proline stabilize β-turns in both trans (in 
position i+1 of βI or β II turns) and cis (in position i+2 of β VIa-turn) configurations.  In 
general, (R)-proline and (R)-amino acids preferentially form β II (i+1) turns.21,22  The 
biological and pharmaceutical importance of these turns will be discussed in Chapter 3. 
Another important feature in proteins and peptide chemistry is the disulfide bond which is the 
result of covalent sulfur-sulfur bond formation (Figure 5) between two non-adjacent cysteine 
residues.  This bond plays a major role in determining the overall 3D shape of peptides and 
proteins.19,21,23   
History of peptide synthesis 
In biological systems peptides and proteins are synthesised through a complicated process.  
Each natural peptide or protein sequence represents its own genetic information flowing from 
deoxyribonucleic acid (DNA) to messenger ribonucleic acid (mRNA) then to the target 
sequence of peptide and protein.20  The first successful attempt to synthesize a peptide in the 
laboratory was achieved by Emil Fisher in 1901.  Despite the fact that proteins and peptides 
are responsible for regulating the overall biochemical process in complex organisms, research 
in this field was neglected until the 1960s when the revolution of increased sensitive 
analytical techniques were possible.  Sanger in 1950 reported the elucidation of the sequence 
of bovine insulin (Figure 5) which is a polypeptide classified as a hormone secreted from the 












interchain disulf ide bridges
an intrachain disulfide bridge
 
Figure 5: Schematic diagram for insulin19  
Three years later, Vincent du Vigneaud (winner of the Nobel Prize in chemistry in 1955) 
synthesised Oxytocin (Figure 6) as the first short peptide to be applied for pharmaceutical 
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purposes.19  Oxytocin is a hormone with many physiological functions such as regulating 




Figure 6: Oxytocin19 
Since then the synthesis of biologically active peptides and the development of advanced 
methods to synthesise more complex peptides, received significant attention.  
Methods of peptide synthesis  
Methods for synthesising peptides have undergone considerable improvements over the 
years.  These methods include classical or solution methods, solid phase peptide synthesis 
(SPPS) and finally a recombinant DNA method.21  The recombinant DNA method is a 
genetic engineering technique which was introduced in the 1980’s.19,21  This method is useful 
for the synthesis of large amounts of natural peptides and proteins such as insulin.21  The 
general idea of this technique is to introduce the coded DNA responsible for the synthesis of 
the target peptide or protein into a micro-organism cell (bacteria) which will then synthesise 
the required protein.  These cells have the remarkable ability to be cultivated in relatively 
short time and can synthesise long peptides and proteins without any errors.19  This method is 
currently only available for natural proteins of which the specific gene is known.    
The synthesis of other peptides and proteins are therefore still largely dependent on chemical 
synthetic techniques.  Initial attempts made use of homogeneous solution phase chemistry.21  
However, due to the problems encountered with classical solution methods an alternative 
strategy was desperately required.  Some of the difficulties inherent to homogeneous 
synthesis are: purification problems which is required after each coupling step (this is 
extremely time consuming), the low yields obtained for the total peptide sequence and 
sometimes the low solubility of the intermediate segments in normal organic solvents.19,24  
Most of these difficulties are brilliantly eliminated with solid phase peptide synthesis (SPPS).  
It is therefore not surprising that SPPS has become the method of choice for the synthesis of 
small scale peptides.24  However, solution synthesis still remains the dominant method for 
large and commercial scale peptide synthesis.21  
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SPPS makes use of C to N coupling (C → N) which has several advantages.  C → N coupling 
in SPPS implies that the N-protected amino acid is coupled with its acid group onto the 
amino group of an amino acid which is already attached to the resin.  SPPS can be 
summarized into four main steps:21,24,25 
• Anchoring of the protected amino acid to the solid support resin (see Figure 7 and 8).  
Depending on the chemicals required (acid or base) for the synthesis and the 
environment of the desired peptide (e.g. peptide amide or peptide acid), the resin 
should be chosen carefully.  The anchor of the protecting amino acids usually results 
from an esterification reaction (resin/linker with an alcohol terminal group) or through 
an amide bond (resin/linker with an amino terminal group).  The first anchoring 
method will yield a peptide acid and the second a peptide amide upon stripping of the 
peptide from the resin.  
• Cleavage of the temporary protecting group on the Nα-amino acid, should take place 
before coupling of the next amino acid to the sequence.  With the SPPS technique 
there are two major protecting groups, namely 9-Flourenylmethyl chloroformate 
(Fmoc) and Di-tert-butyl dicarbonate (t-Boc).  The t-Boc group is acid labile 
[Trifluoroacetic acid (TFA) is in most cases used for cleavage], whilst the Fmoc 
group is sensitive towards mild basic conditions especially secondary amines.  Its 
stability towards acidic media allows the application of acid-labile semi-permanent 
protecting groups such as t-Boc on the side chain functional groups of the amino acid.  
The protecting group cleavage is followed by a thorough washing procedure to 
remove all by-products, unreacted reagents etc.  The elegant mechanism of 
deprotection for the Fmoc group is illustrated in Scheme 1. 
•  SPPS makes use of in situ coupling which is the most efficient and easiest coupling 
method.  Methods were developed in which the carboxylic function of the N-
protected amino acid is activated for more facile coupling to the free amino group 
attached to the solid support.  Different in situ coupling reagents (Figure 9) are used 
for this and the main function is to activate the carboxylic group.  These two steps as 
mentioned above (cleavage of the protecting group and coupling of the next amino 
acid) are repeated a number of times until the target peptide is obtained.  As 
explained, the impurities (by-products and the other reagents) are removed after each 




• Cleavage of the desired peptide from the solid support is the final step in the SPPS 
method in which breaking of the covalent bond between the resin/linker and the 
peptide take place.  Acidolysis† with concentrated TFA is widely used for cleaving 
the peptide off the resin and simultaneous cleavage of the protection group (e.g. t-
Boc) off of the peptide.  Synthesis of t-Boc and t-Butyl protected peptides require an 
acid sensitive linker/resin in order to prevent deprotection of these groups.  The 
Barlos resin 16, Sasrin resin 19 and Sieber acid resin 20 require between a 1-10% 












18: Wang resin X = H,
19: Sasrin resin X = CH3-O,
15: HMPB resin 16: Trityl choloride resin (Barlos






20: Sieber acid resin
 
Figure 7: Example of peptide acid resins24 
All of the resins above will yield peptide acids upon cleavage of the peptide from the resin.  It 
appears that in most cases the resin will form a stabilised carbocation in the process.  In many 
cases Triisopropylsilane (TIS) or 1,2-ethanedithiol (EDT) are widely use as cation 
scavengers.25 
Examples of peptide amide resins are provided in Figure 8.  The same principle holds as 
above.  A cation will form upon removal of the peptide amide and the lone pair of electrons 
on the ether oxygen atoms attached to the aromatic rings are utilized to alleviate the effect of 
                                                 
† Acidolysis is scission of a bond via adding H+ X-, while hydrolysis involves adding of H+OH- 
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the carbocation.  The carbon to amide bond is weakened by the acidic conditions, assisted by 












21: Rink amide resin
24: 2-Chlorotrityl amide resin  
Figure 8: Examples of amide peptide resins24 
A schematic representation of the mechanism of Fmoc deprotection is provided in Scheme 1.  
The driving force is the fact that the negative charge can be delocalised over three rings (13 

































Scheme 1: Deprotection of Fmoc using piperidine21 
Coupling agents are required for activating the incoming acid and to remove the equivalent of 
water that forms during amide bond formation.25  Initially carbodiimide reagents e.g. 
diisopropylcarbodiimide (DIC), carbodiimide ethyl(3-diethylaminopropyl)-carbodiimide 
hydrochloride (EDC) were popular coupling agents.  Problems with the use of carbodiimides 
in the SPPS technique included the formation of insoluble urea by-products and weak 
coupling efficiency when N,N-Dimethylformamide (DMF) is used as solvent.25  Figure 9 
provide an example of more efficient and popular SPPS coupling agents discovered over the 
years.  The effectiveness of these phosphonium and uronium salts stems from the rapid 
ability to form the corresponding ester, the formation of soluble secondary products and the 



















































38: HOBt  
Figure 9: Example of the most common SPPS activation reagents24,25 
All these SPPS steps can be performed manually where the coupling and deprotection steps 
are usually monitored by applying the ninhydrin test on a few beads of the resin.24  In Fmoc 
chemistry, the absorbance of the reaction solution is another method for monitoring the 
coupling and the deprotection steps.  This is due to the strong absorbance of the 
dibenzofulvene-piperidine adduct 31.  An absorbance increase after the deprotection and a 
decrease after the coupling in each step as indicative of the efficiency of the reaction.21,25  
In 1966 R.B Merrified developed the first automated peptide synthesiser, nowadays many 
new improved generations of automated peptide synthesis have been developed.21,24  In 
automated peptide synthesis methods, the steps can be monitored by either recording the 
conductivity of the reaction solution or by the absorbance of the reaction when using Fmoc 
synthesis.21  The latest peptide synthesisers also make use of microwave synthesis, which 
allows for faster and more effective coupling.26  Our group is in the privileged position to 
have access to an automated microwave assisted SPPS instrument (see details in the 





Cage amino acid peptides  
Incorporation of unnatural polycyclic amino acids into short peptide sequences has been of 
major interest especially in the pharmaceutical field.  This is due to the ability of such amino 
acids to cross the cellular membrane and to reduce the degradation rate of the peptide in 
biological systems due to the steric hindrance imposed on the peptide bond.27  The following 













Figure 10: Some examples of polycyclic unnatural amino acids27-30 
A computational investigation in our group focussing on the incorporation of the PCU amino 
acid 41 and the trishomocubane amino acid 42 into short peptide sequences have been 
conducted.31-33  Previous attempts to incorporate these cage amino acids into peptides were 
made with limited success.30,34,35  Initially attempts were conducted with the PCU amino 
acid 4130,34 and it was thereafter decided to use the trishomocubane skeleton 42 since it 
would impose less steric hindrance.29,35  Achiral glycine was initially used and was suspected 





































Figure 11: A possible Schiff base formation 29 
Alanine was suggested to replace the glycine unit to overcome this problem, the reason being 
that the methyl group in the alanine side chain could prevent the formation of the Schiff base.  
Also, the methyl group is expected to be small enough to avoid steric hindrance thus allowing 
coupling to the cage amino acid.  Alanine peptides, according to an electron spin resonance 
study (ESR), prefer 310-helix β-turns.
36  Previous attempts in our group to manually 
synthesize Ala-Ala-Ala-Tris-42-Ala-Ala-Ala-Ac (Figure 12) was only partially successful.29  
A correct MS peak was observed, but poor NMR spectra’s were achieved.  Collaboration 
with a group at Uppsala University (Sweden) resulted in the successful synthesis of the target 





































Figure 12: The structure of Ala-Ala-Ala-Tris-42-Ala-Ala-Ala  
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The X-ray study of the cage peptide indicated that the trishomocubane amino acid 42 is 
indeed a very active β-turn inducer and confirmed the computational predictions previously 
made.22  As pointed out, a number of efforts to manually synthesise the hepta-peptide Ala-
Ala-Ala-PCU-41-Ala-Ala-Ala were unsuccessful.  Part of this dissertation focuses on the 
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SYNTHESIS OF HYDANTOIN DERIVATIVES  
Introduction 
The chemistry of hydantoin derivatives has been of major interest to 
pharmaceutical/medicinal chemists for many years.1,2  This is mainly due to the potency and 
promising activities of hydantoin derivatives in various pharmaceutical applications such as 
anti-microbial, anti-type-II diabetes (non-insulin dependent), zinc metaloprotease inhibitors 
and anti-convulsant agents.3-6  Hydantoins (Figure 13) are heterocyclic five membered ring 













Figure 13: Hydantoin ring  
Phenytoin [(5,5 diphenyl hydantoin)] 47 was the first clinical anti-convulsant drug for 
electronic shock animal mode of seizure.2  Phenytoin was introduced over seven decades 
ago,2 and according to the American Academy of Neurology (2005), it is still the most 
prescribed drug for initial therapy.2,7-9    
Normally, an epileptic seizure causes sudden release of abnormal electrical impulses in the 
brain resulting in temporary disorder of the normal activity passing through the neuron 
cells.10  These seizures are classified as two types:11 
• General seizure which is the common type, where the seizure starts in a part of the 
brain and then spreads to other regions.  
• Partial seizure which occurs only in a small part of the brain. 
The mechanism of action for hydantoin ring /phenytoin is still unclear, but it is believed to 
act through the blockage of sodium channels and/or Na-K-ATPase (Na-pump) in the brain 
cells, thereby reducing the high frequency of epileptic seizure.2,8,12-14 
20 
 
It was reported that substitution at position one of the hydantoin ring of phenytoin decreases 
its potency as an anticonvulsant, in contrast to substitution at position three.7,15,16  Although 
the nitrogen atom at position three on the hydantoin ring is less nucleophilic than the nitrogen 
atom at position one, the chances of getting substitution on position three increases with an 
increase of steric bulk on the carbon atom at the five position.  
Due to the low solubility and the bio-availability of phenytoin, considerable efforts were 
made to improve these properties, by introducing different substituents on the N-3 position or 
via substitution of the phenyl ring.7,8,17,18  Fosphenytoin 48 is a water soluble prodrug‡ of 
phenytoin marketed under the trade name Cerebyx.19  It metabolises in biological systems to 
yield phenytoin (the active compound), phosphate and formaldehyde which then converts to 
formate.19  
Other active compounds reported involved the replacement of the phenyl groups at the C-5 
position.20  It is obvious that the phenyl ring and aliphatic chains (see Figure 14) are 
necessary to improve the lipophilicity of the drug.    
 
                                                 
‡ A prodrug is an inactive form of drug which needs be metabolically converted to the active form in the 





























49 50   
Figure 14: Examples of hydantoin derivatives applied as anticonvulsants1,7,8 
However a balance between hydrophilic and lipophilic properties (amphilicity) is necessary 
for designing this type of bioactive compounds, since it allows them to circulate in biological 
system and achieve their target (cross the BBB).21  Introducing polar groups (e.g. phosphate, 
carboxylic ect) to the parent compound is a popular approach to increase the amphilicity of 
the drug.21,22  
The importance of polycyclic cage compounds in terms of biological applications was 
discussed in Chapter 1.  Two proposed cage analogues of Cerebyx are compounds 51 and 52.  
It is envisaged that the cage skeleton which is known to cross the BBB and CNS (as was 





















Figure 15: Structures of the proposed hydantoin derivatives 
The proposed retro synthetic pathway for the synthesis of 51 and 52 is presented below.  The 

















































Scheme 2: The proposed retro synthetic scheme for compounds 51 and 5223   
The next sections describe the attempted synthesis of compounds 51 and 52  
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Synthesis of adamantane hydantoin analogues  
Synthesis of the adamantane hydantoin 5925,26 was achieved via the Bucherer-Lieb27 method.  
adamantanone 61 is reacted with sodium cyanide, ammonium carbonate and ammonium 
hydroxide in ethanol producing 59 in 89%.yield. 
Note that Adamantanone is commercially available and can be used without further 























Scheme 3: Synthesis of adamantane hydantoin 5925   
Compound 59 doesn’t have a chiral centre due to the plane of symmetry which crosses each 
of the following atoms: C-6, C-5, C-7, C-2, N-1’, C-2’, N-3’ and C-4’.   
The adamantane hydantoin was further reacted with formaldehyde 62 in the presence of a 































Scheme 4: Synthesis of novel compound 57 
The 1H NMR spectrum of compound 57 showed the absence of the singlet at 10.48 ppm 
assigned to the N-3’ position and the presence of a singlet integrating to two protons at 4.67 
ppm which was assigned to the 5’ protons.  The N-1’ proton shifted from 8.38 ppm to 8.71 
ppm.   
The 13C NMR spectrum of compound 57 displays a signal at 60.2 ppm representing the C-5’ 
position while the carbon signals at 154.7 and 174.9 ppm show HMBC correlation to H-5’ 
representing the C-2’ and C-4’ respectively on the hydantoin ring.  These assignments 
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correlate to those by Martins et al. for the PCU hydantoin 60.28  The C-2’ and C-4’ shifts for 
this study were assigned to each of the compounds 55-58 based on the results by Martins et 
al. 
Reacting a suspension of compound 57, p-toluenesulfonyl chloride (tosyl chloride) 63 and 
triethylamine in THF at room temperature for 12 hours gave 55 in 73% yield.  Attempts to 
remove triethylamine via aqueous extraction and silica gel chromatography resulted in 






































Scheme 5: Synthesis of novel compound 55 
The 1H NMR spectrum of compound 55 shows a singlet at 4.71 ppm for the two methyl 
protons at the H-5’position.  The N-1’ proton of 55 has shifted to 9.22 ppm from 8.71 ppm 
for the starting material 57.  This is due to the introduction of the electron withdrawing tosyl 
group present in compound 55.  Electron withdrawing groups cause (through delocalization 
in the ring) the N-1’ proton to be more de-shielded, hence it will register at a higher 
frequency.  The 13C NMR spectrum shows a peak at 20.7 ppm for the C-10’ carbon on the 
tosyl group; the peaks at 125.4, 128.0, 145.6, 153.9 ppm belong to the aromatic ring carbons.  
The two carbonyl carbons C-2’and C-4’ in the hydantoin ring are observed at 154.0 and 
176.0 ppm respectively.  
Synthesis of PCU hydantoin analogous  
The starting material for the synthesis of PCU hydantoin 60 is pentacyclo-
[5.4.0.0.2,6.03,10.05,9]undecane-8-one (PCU monoketone 64) which was synthesized from the 
PCU-8,11-dione 73.  Note that the synthesis of 64 will be discussed at the latter part of this 
chapter in order not to disrupt the flow of the current theme.  It is important also to note that 
the monoketone 64 starting material is normally obtained as a racemate.28  However, it is 
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possible to obtain it in optically pure form by using a horse liver alcohol dehydrogenase 
enzyme.29 
The PCU hydantoin 60 was synthesized via a similar synthetic pathway as described for the 








64 60  
Scheme 6: Synthesis of PCU hydantoin 6015,28   
Compound 60 above was further derivatized using similar conditions as reported for the 



























































Scheme 7: Synthesis of novel compounds 58 and 56 
All attempts to purify compound 58 through silica gel chromatography were unsuccessful due 
to degradation to the starting material 60.  Recrystallization of 58 from ethyl acetate resulted 
in the pure form.  
The N-3’peak in the 1H NMR spectrum of compound 58 is absent while the corresponding 
signal for compound 60 is observed at 10.49 ppm.  The signal registering at 4.68 ppm is 
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assigned to the methylene protons of H-5’ while the triplet peak at 6.20 ppm was assigned to 
the -OH group; these assignments were based on (a) the proton integration values, (b) the fact 
that the peak at 6.20 ppm exchanges with D2O and (c) the observed COSY correlation 
between H-5’ and O-H.  The signal at 7.91 ppm was assigned to the N-1’ proton on the 
hydantoin ring.  The 13C NMR spectrum of compound 58 shows a peak at 60.4 ppm which 
was assigned to C-5’ while the carbon atoms associated with 156.2 and 176.5 ppm which 
show HMBC correlation to H-5’.  These carbon atoms were assigned to the carbonyl carbons 
C-2’ and C-4’ respectively.  The assignment for the C-5’ was confirmed by the correlation in 
the HSQC spectrum with the corresponding hydrogens (H-5’, 4.68 ppm).   
The 1H NMR spectrum of compound 56 shows a singlet peak for N-1’ at 8.44 ppm.  This 
corresponding peak had shifted from 7.91 ppm for compound 58 and is similar to what was 
observed for the corresponding adamantane analogue 55 as discussed above.  The absence of 
the –OH peak observed in compound 58 at 6.20 ppm also confirms the successful synthesis 
of compound 56.  Doublet signals were observed at 7.12 and 7.48 ppm, which were assigned 
to the aromatic protons of the tosyl group while the singlet at 2.27 ppm was assigned to C-10’ 
of the tosyl group.  The 13C NMR spectrum shows a peak at 20.7 ppm for C-10’; the peaks at 
125.4, 128.1, 138.0, and 145.2 ppm were assigned to the aromatic ring.  
The next step in the project was to attempt the attachment of a phosphate groups to the side 
chains. 
Attempted synthesis of dibenzyl phosphate derivatives of PCU and adamantane   
According to the synthetic route for Fosphenytoin,23 compounds 55/56 should be treated with 
dibenzyl phosphate 64 in the presence of a base in an organic polar solvent to give the 































Scheme 8: Attempted synthesis of compounds 53 and 54 
The procedure from literature for the synthesis of Cerebyx19 was followed but this synthesis 
of 53/54 was unsuccessful.  Different solvents such as tetrahydrofuran, dichloromethane and 
acetonitrile were used under various conditions (room temperature and refluxing) with 
different bases (such as triethylamine, sodium hydride and sodium hydroxide).  The reactions 
were monitored up to 24 hours and showed no sign of product formation using TLC analysis 
and NMR spectroscopy, only starting materials were observed. 
It was then decided to use bromine as a leaving group instead of the tosyl group.  First, the 














Scheme 9: Synthesis of novel compound 65 
Compound 65 was refluxed with dibenzylphosphate in DCM in the presence of KOH as base 






























Scheme 10: Attempted synthesis of compound 53 
Applying the same technique for the synthesis of the PCU hydantoin bromide 65 proved to be 
futile as the reaction workup resulted in the isolation of the PCU hydantoin 60 as was 




















Scheme 11: Attempted synthesis of compound 66 
Based on the previous unsuccessful attempts, a new synthetic pathway was designed (Scheme 
12).30  This reaction was also unsuccessful as the only products identified via TLC and NMR 




























Scheme 12: Attempted synthesis of compounds 51 and 52 
It was decided that the proposed synthesis of 51/52 was sufficiently exhausted and that this 
part of the project would not be pursued further.  The following section describes the 
synthesis of the PCU mono ketone 64 as starting material for the PCU hydantoin 60.  
Synthesis of PCU mono ketone 64 
The starting material for the PCU mono ketone 64 is the dione 73.  The dione was 
synthesized31 by reacting cyclopentadiene 69 with p-benzoquinone 70.  This reaction takes 
place via a Diels–Alder mechanism ([4+2] cycloaddition reaction) to form 5,8-methano-
4a,5,8,8a-tetrahydro-1,4-naphthoquinone 72 which upon irradiation with UV light resulted in 






















Scheme 13: Synthesis of the PCU dione 7331 
The mechanism of converting the adduct 72 to PCU dione 73 was initially considered to be a 
concerted photochemical [2+2] cycloaddition reaction.31  The concerted cycloaddition 
reaction for 4n π-electron type of molecules are thermally not allowed but photochemical 
possible.  This is attributed to the symmetry forbidden overlapping between the two double 
bonds while they are in ground state.  Excitation with UV light excites one of the double 
bonds and cause promotion to one of its electrons from π to π* as indicated below (“π” 
indicates the ground state filled π-orbital and “π*” indicates the excited state (empty or filled) 










Figure 16: Photochemical excitation of the alkene bond32 
According to the Hofmann Rules, the following electronic changes occur during the 
reaction.32  Combination of the alkene exited state with the ground state one, results in two 
different energy molecular orbitals for each of π- and π*-electronic states (Figure 17).32  In 
the case of the π-orbitals, two electrons are in the lower energy orbital and one is present in 
the higher molecular π-orbital.  The only π*-excited electron collapses to a lower π*-orbital.  
The result is that three electrons are located in a low energy molecular orbital and one 
electron is excited allowing for the cyclization to take place.32  The two single electrons have 
opposite spins, which simplifies the process of bond formation.    




Figure 17: Electrons distribution in π and π* orbitals after combining the alkene excited 
state with the ground state32   
A subsequent computational study of this mechanism using ab initio software revealed a di-
radical step wise mechanism is possible which takes place through the triplet exited state 















































Scheme 14: Ab initio calculated mechanism for adduct cyclisation33 
Formation of the 75 (triplet) enedione  through the first singlet excited state, 74, requires 
relatively high energy (99 kcal/mol) in order to promote one of the nonbonding electrons on 
the oxygen atom from the n- to π*-orbital.33  The one unpaired electron of 75 (from the π-
orbital in 74) interacts to form the first new carbon-carbon cyclization bond in the transition 
state 76.33  Homolytic cleavage of the π-orbital of the other alkene will yield the diradical 76 
(72 kcal/mol) in which both radicals have the same spin direction.  This step (formation of 
77) was suggested to act as the rate determining step for this reaction.  Finally 73 is obtained 
through the exothermic reaction after the one radical electron undergoing a change in spin to 
allow for cyclization of the precursor 77.33   
Synthesis of the PCU mono-ketone 64 was achieved following a series of well established 
reactions.  The reaction started with protection of one of the carbonyl groups of the dione as a 
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73 78 79  
Scheme 15: Synthesis of the PCU keto-ketal 7934 
Due to steric effects, the monoethylene ketal (keto-ketal) 79 is obtained as the only product, 
even with modest excess ethylene glycol.  Since the reaction is performed under non-chiral 
conditions, both enantiomers 79a and 79b are obtained in 88% overall yield.   
O
O O O O
O
79a 79b  
The mechanism of this reaction is described below.  It is known that nucleophilic attack on 
the dione 73 almost exclusively occurs from the exo-face of the cage.35,36  In order to 
simplify the reaction mechanism, only one enantiomer will be used for all subsequent 


































Scheme 16: Proposed mechanism for keto-ketal 79 synthesis37 
Sodium borohydride was employed to reduce the carbonyl group on the ketal 79 to the 
alcohol 87.34,35  The reduction product, 11-hydroxy-pentacyclo[5.4.0.02,6.03,10.05,9]undecane-
8-one-ethylene ketal (hydroxy-ketal) 87, was deprotected using 10% HCl (v/v) to obtain 11-















79 87 88  
Scheme 17: Synthesis of hydroxy-ketal 87 and hydroxy-ketone 8834,35 
Exo nucleophilic attack of the hydride ion on the carbonyl group gives hydroxyl ketal 87.  
Deprotection of the ketal group proceeds via protonation of the oxygen atom followed by SN2 
nucleophilic attack of water.  This step is repeated for the other oxygen atom on the ketal 















































Scheme 18: Proposed mechanism for synthesis of the hydroxy-ketone 8837 
Reduction of the carbonyl group to methylene was carried out by refluxing the hydroxy-
ketone 88 with hydrazine hydrate followed by addition of excess of KOH.  The volatile 
pentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-ol (endo-PCU alcohol) product 94 was purified 











Scheme 19: Synthesis of the PCU alcohol 9435 
The proposed mechanism for this reactions is presented in Scheme 20.  Hydrazine attacks the 
carbonyl carbon forming the hydrazone 96 after elimination of the hydroxyl group.21  The 
hydrazone undergoes further decomposition in presence of base forming the alkyldiimide 99.  


























































Scheme 20: Proposed mechanism for PCU alcohol 94 synthesis37 
Oxidation of the PCU alcohol 94 was achieved utilizing Jone’s reagent, chromium tri-oxide 





101 O94 64  
Scheme 21: Synthesis of PCU mono ketone 6435 
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SYNTHESIS AND INCORPERATION OF THE PCU AMINO ACID 
INTO SMALL PEPTIDES 
Introduction  
In biological systems specific protein-protein interactions are responsible for regulating many 
biological processes.1  Some of these processes are naturally initiating in the biological 
system e.g. immune responses, while other processes are inhibiting e.g. apoptosis.1,2  
Peptidomimetics are small/shorter modified peptides synthesised in the laboratory to mimic 
natural proteins/peptides in terms of the 3D space required to interact with the biological host 
system.2  When the peptidomimetics bind to the host, it prevents the natural protein-protein 
interaction and subsequently inhibits the process that initiates from the normal protein-protein 
interaction.3   
However, peptides with low molecular (less than 500) weight have a high degradation rate in 
the biological system (short half life time) coupled with rapid excretion by the kidney and the 
liver.4,5 
The design of peptidomimetics depend on the structure–activity relationship (SAR) of the 
guest (peptidomimetics) with the host (e.g. enzyme, DNA) in order to identify the active side 
and its three dimensional arrangement.6  Peptidomimetics are basically classified into three 
types as6 
• Type I: The design of the peptide mimic (sometimes atom for atom) the parent 
peptide backbone.  
• Type II: Also known as functional mimetic: These are non-peptide molecules which 
bind to the active site of the peptide. 
• Type III: The design of the mimic peptide is not related to the parent peptide/protein, 
but still contains the required scaffold and groups to bind with the active site of the 
host system.  
In many cases α-helices and β-turns are responsible for protein host systems (enzymes, 
hormones) to identify their partner/guest molecule.  Note that DNA sequences can also 
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operate as a host system which can interact with a guest molecule to induce a certain 
biological reaction.7,8  This resulted in an increased of research into the design of 
peptidomimetic molecules.  Incorporation of unnatural amino acids into the peptidomimetic 
sequences became a widely used method for stabilised conformations especially for adopting 
the different possible β-turns.7,9    
Part of the research interests in the GGKM group§ is to study the influence of the 
incorporation of polycyclic cage amino acids into short peptides.10-12  These studies revealed 
that cage moieties serve as very active β-turn inducers.  As indicated in Chapter 1, the 
synthesis of PCU amino acid 41 containing short peptides had not yet been achieved.  The 
challenge therefore remained to successfully synthesise such a peptide and to determine (if 
possible) its X-ray structure.  The next section describes the synthesis of PCU amino acid 
peptides.   
Synthesis of Fmoc PCU amino acid   
The established method for the synthesis of polycyclic amino acids proceeds via hydrolysis 
of the corresponding hydantoin derivatives.13-16  In our laboratory alternative methods were 
explored that involve the hydrolysis of bis-t-boc protected PCU hydantoin 104 with aqueous 












Scheme 23: Hydrolysis of bis-t-boc protected PCU hydantoin 
The method which was applied in this dissertation involves direct hydrolysis of the PCU 
hydantoin in a medium pressure reaction vessel using sodium hydroxide (Scheme 24).   
                                                 












Scheme 24: Hydrolysis PCU hydantoin  
Due to the solubility problem of PCU amino acid 41 in water and organic solvents, 
characterization (NMR analysis) was performed on the Fmoc derivative 106.  An aqueous 
solution of 41 was adjusted to pH 9 and Fmoc-Cl 105 in dioxane was added with stirring for 
24 hrs at room temperature, providing 106 in 73 % overall yield.  While the alternative 














Scheme 25: Synthesis of Fmoc PCU amino acid 106 
As discussed in Chapter 2, two enantiomers of the PCU hydantoin were obtained, leading to 











106a 106b  
These Fmoc protected amino acids were used as a racemate in the peptide synthesis described 
next. 
Synthesis of (Ala)3-PCU-41-(Ala)3-Fmoc 
SPPS techniques were used for the synthesis of the target peptide on Rink amide resin.  
Monitoring the coupling of the first alanine into the Resin-(Ala)3-PCU-NH2 sequence was 
problematic as a positive result with the ninhydrin test could not be observed, even upon 
extended reaction times.  This was attributed to the steric hindrance exerted by H-11s on the 
amino group at C-8 (see Figure 18).18 
The target peptides were successfully synthesised using the microwave automated peptide 
synthesiser.  The representation of the sequence of reactions that was followed is shown in 
Scheme 26.  The complete experimental details are provided in Chapter 5.  As with the case 
with the trishomocubane amino acid 42,18 a diastereomeric mixture of peptides was obtained.  
Two diastereomeric peptides were obtained since (S)-Ala was used with (R)- and (S)-106a 
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Scheme 26: Synthesis of (Ala)3-PCU-(Ala)3-Fmoc using automated microwave synthesis 
Unlike the trishomocubane peptide sequence 45, it was decided to leave the Fmoc protecting 
group on the peptide in order to assist in separating the diastereomers after unsuccessful 
attempts to separate them when unprotected.  Two dimension NMR spectra were obtained on 
the separated diastereomeric sample at retention time 11.45 minutes (see experimental details 
in Chapter 5).  The other diastereomer at 12.28 minutes was obtained in too low a yield for 















































































Figure 18: (Ala)3-PCU-(Ala)3-Fmoc peptide 
NMR elucidation of the peptide sequence (Ala)3-PCU-(Ala)3-Fmoc 107. 
NMR and the electro spray ionization (ESI) mass spectroscopy were used to confirm the 
successful synthesis of the desired product.  Since the peptide was dissolved in deuterated 
methanol (CD3OD), it was expected that deuterium exchange would take place with the 
amide hydrogens.  ESI mass spectra showed a molecular ion peak at 880 [M + 23(Na) + 4 
(4D+)].  In order to confirm the structure of the peptide product from the NMR spectra, firstly 
the presence and structure of the PCU amino acid 41 (segment PCU-4, Figure 18) was 
established, thereafter that the rest of the peptide structure was confirmed.  Possible NOESY 
interactions between the different amino acid segments was searched for in an effort to 
establish information about the 3D structure of the peptide. 
When the NMR of the cage amino acid is considered, one should realize that all the methine 
carbons are chiral.  Nevertheless, the skeleton exhibits a reasonable symmetric character, 
especially for groups further removed from α-carbon (C-8).  Previous NMR studies on 
smaller cage structures managed to assign each of the proton and carbon signals 
individually.19,20  A very handy approach to elucidate the NMR spectra of the cage amino 
acid 41 is the fact that the coupling constants for the two CH2-groups are known.
16  It is 
important to note that the protons on each methylene group are in a different environments 
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due to the asymmetric nature of the cage moiety, also since there is no free rotation possible 
in the rigid cage skeleton. 
The 1H NMR spectrum of the peptide 107 shows a pair of doublet peaks for H-4a and H-4s at 
1.23 and 1.71 ppm.  These protons exhibit a COSY and NOESY correlation to each other 
with a coupling constant of about 10.35 Hz.  The other pair of doublets were assigned to H-
11a (0.96 ppm) and H-11s (2.06 ppm) and also shows similar COSY and NOESY correlation 
to each other with a coupling constant of about 13.0 Hz.  These coupling constants are similar 
to that of the PCU hydantoin 60.16 
The signal at 2.2 ppm shows COSY and NOESY correlation to H-4a and H4s and could be 
assigned to H-3 or H-5.  H-11a exhibits a COSY and NOESY correlation with a signal at 
2.46 ppm, whilst the latter shows a COSY and NOESY correlation to the signal at 2.2 ppm.  
This cross correlations enables one to assign the signal at 2.26 and 2.46 ppm to H-3 and H-10 
respectively.  The resonance at 2.58 ppm shows a COSY correlation with H-4a and a NOESY 
correlation with both H-4a and H-4s; through elimination this signal was assigned to H-5.  
Both H-10 (2.4 ppm) and H-5 (2.5 ppm) exhibit COSY and NOESY correlations with a peak 
at 2.8 ppm, which was assigned to H-9.  The signal at 2.73 ppm shows a COSY correlation to 
H-11a and a NOESY correlation to both H-11a and H-11s; through elimination this 
resonance was assigned to H-1.  A COSY correlation was observed between a signal 
registering at 2.73 ppm and with the two methine protons H-1 and H-3.  It also exhibits a 
NOESY correlation with the resonance at 2.73 ppm and H-3 only.  The only remaining 
proton that satisfies these correlations is H-2 (2.73 ppm).  The resonance at 3.28 ppm was 
assigned to H-7 because of an observed NOESY and COSY correlation with H-1.  The 
COSY and NOESY correlations of H-7 and H-2 with a signal overlapping with H-5 at 2.58 
ppm was assigned to H-6 (also at 2.58 ppm).  The HSQC spectrum was used to identify the 
carbon signals of all assigned protons, however the identification of C-5 and C-6 seems 
















Table 1: 1H and 13C NMR dataa for PCU-4 skeleton  
PCU-4 
Atom δ1Hb J(Hz) δ13Cb 
1 2.73 - 33.6/36.2 
2 2.62 - 41.25 
3 2.26 - 46.5 
4a 1.23 10.35 33.6 
4s 1.71 10.35 33.6 
5 2.57 - 40.5/44.1 
6 2.57 - 40.5/44.1 
7 3.28 - 40.5 
8 - - 65.4 
9 2.85 - 46.5 
10 2.46 - 42.4 
11a 0.96 13.0 28.4 
11s 2.06 13.0 28.4 
                                        a 600MHz for 1H and 150MHz for 13C.  
                                        b Solvent CD3OD.  
The next section describes as far as possible the observed NMR signals for the rest of the 
peptide sequence. 
Using the APT 13C NMR spectrum, the six alanine methyl carbons registering at 15.53-16.42 
ppm were identified.  These carbon signals show HSQC correlation to multiplets registering 
in the region 1.25-1.56 ppm, which were assigned to all eighteen protons belonging to Ala-Hβ 
(CH3) in the sequence.  This region (1.25-1.56 ppm) shows COSY and NOESY correlations 
to three multiplet signals (4.02 (2H), 4.15 (3H) and 4.24 (2H) ppm).  Those peaks were 
assigned to the all six Ala-Hα protons in the sequence.  As mentioned earlier, all eighteen 
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Ala-Hβ (CH3) appears in regions 1.25-1.56 ppm and due to these intense overlapping each 
Ala-Hβ cannot be individually assigned.  However, from the HSQC spectrum it is clear that 
the carbon signals of all eighteen Ala-Hβ (CH3) appears at 15.5, 15.8, 16.1, 16.44 ppm, where 
the first peak seems to be overlapping with the other two Ala-Hβ (CH3) groups.  The Ala-Hβ 
protons show HMBC correlation with the carbonyl carbons attached to Ala-Cα registered at 
173.8, 174.3, 175.1, 175.6 and 175.7 ppm.  Also, observed in the HMBC spectrum is the 
correlation of the Ala-Hβ with the Ala-Cα regions, further confirming the assignment of the 
methyl groups.   
The next section will focus on the elucidation of the Fmoc part of the peptide sequence.  Two 
multiplet resonances at 4.41 and 4.52 ppm show COSY and NOESY correlation with each 
other and both correlate to a carbon signal registering at 66.9 ppm as illustrated in the HSQC 
spectrum.  These resonances were assigned to H-1a’ and H-1b’ respectively since both H-1a’ 
and H-1b’ shows a COSY correlation to a peak at 4.25 ppm (overlapping with one Ala-Hα) 
which was assigned to H-2’.  The HMBC spectrum shows a correlation of H-1a’ and H-1b’ 
with a quaternary carbon at 143.9 ppm, this was assigned to C-8’.  Also evident on the 
HMBC spectrum, are the correlations of C-8’ with H-2’ and two unknown signals at 7.35 and 
7.85 ppm which are probably H-4’ and H-6’.  However, only the peak at 7.35 ppm shows 
NOESY and COSY correlation to two signals at 7.43 and 7.69 ppm; based on the Fmoc 
structure the signal at 7.35 ppm was assigned to H-4’ while that at 7.85 ppm was assigned to 
H-6'.  H-6’ (7.85 ppm) exhibits a COSY correlation with 7.43 ppm which was assigned to H-
5’; it follows by way of elimination that H-3’ registers at 7.69 ppm.  The resonances of H-3’ 
and H-5’ show HMBC correlations to a quaternary carbon at 141.3 ppm, this was assigned to 
C-7’.  The above assignments were further verified using the HSQC spectrum with all proton 






















Table 2: 1H and 13C NMR dataa of Fmoc group on the peptide sequence  
Fmoc 
Atom δ1Hb J(Hz) δ13Cb 
1’ 4.41 m 66.9 
1’ 4.52 m 66.9 
2’ 4.29 - 49.3/46.5 
3’ 7.69 - 124.71 
4’ 7.35 - 126.82 
5’ 7.43 - 127.62 
6’ 7.85 - 119 
7’ - - 141.3 
8’ - - 143.9 
                                         a 600MHz for 1H and 150MHz for 13C. 
                                         b Solvent CD3OD. 
The attempts to confirm the existence of a β turn in peptide 107 was attempted by obtaining a 
low temperature (-50°C) NOESY spectrum.  It was hoped that more pronounced NOESY 
interactions between NH and other protons could be observed at lower temperatures.  
However, the low temperature NOESY did not reveal much more.  This was attributed to the 
deuterium exchange between the amide hydrogen and CD3OD.   
After the successful synthesis of the former peptide, it was decided to incorporate the PCU 
amino acid 41 into a short peptide template of the AVPI peptide.  AVPI exhibits anti-cancer 
activity.  A brief introduction on the AVPI peptide template, its activity and the synthetic 
steps of the modified AVPI peptide are provided below.  
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Synthesis of Ala-Val-PCU-Ile 108 
Apoptosis or programmed cell death is an important process for growing and homeostasis** 
in metazoan††.  Although the normal cells are programmed for apoptosis when they are no 
longer in use, cancer cells have the ability to prevent the process using inhibitors binding to a 
number of apoptosis’s enzyme of the general family caspases‡‡. 
X-linked inhibitor of apoptosis protein (XIAP) is one of those inhibitors.  Its potency is 
believed to be the result of selective binding to the two effectors caspases-3 and-7 via the 
Baculoviral IAP Repeats2 (BIR2) domain§§.  It also binds to the peptide linker at caspases-9 
through the BIR3 domain.21,22  XIAP became a research target for designing the 
peptidomimetic sequence aiming to bind with BIR3 and BIR2 to prevent its protein-protein 
interaction with the apoptosis enzyme.  An important discovery was made when it was 
realised that the peptide sequence Ala-Val-Pro-Ile (AVPI, Error! Reference source not 
found.) shows the ability to bind with both the BIR3 and BIR2 domains with Kd values of 
0.4-0.7 μM and 6-9 μM respectively.  Unfortunately AVPI failed in cell permeability tests22 











Figure 19: The structure of AVPI 
Computational results in our laboratory10,12,24 demonstrated that the PCU amino acid can 
promote similar β-turns to/like proline, which is used in AVPI.  The high lipophilic character 
of this cage moiety was discussed in Chapter 1; it was therefore decided to synthesise the 
peptide sequence Ala-Val-PCU-Ile as a potential anti-cancer agent.  Note that the actual 
                                                 
** Homeostasis is the ability of the body to maintain its physiological system at constant condition, despite the 
variation of the environment around it.  
†† Metazoan or kingdom of animalia are multicellular organisms that depend on the other organisms (directly or 
indirectly) for their nutrients. 
‡‡ Caspases part of the cystiene proteases family, play an important role in apoptosis. 
§§ BIR zinc finger domains form part of the IAP protein sequence and play an important role in programmed cell 
death.  They consist of four α-helics, three anti-parallel β-sheets and coordinate with Zn ion through three Cys 




biochemical/microbiology anti-cancer tests of the product falls outside the scope of this 
dissertation.  
Once again the same automated peptide synthesiser and the same approach were used for the 













































Scheme 27: Synthesis of Ala-Val-PCU-Ile  
The peptide was synthesised and purified using HPLC (See the details in the experimental 
section – Chapter 5) and the NMR analysis was done on a separated diastereomeric sample 



















































Figure 20 Ala-Val-PCU-Ile 
The successful synthesis of the peptide was confirmed using (a) ESI mass spectrum shows 
molecular ion peak at 488.4 [M+1] and (b) the NMR spectra which is discussed below.   
NMR elucidation of the peptide sequence Ala-Val-PCU-Ile 108 
The same methodology as for the previous peptide 107 was followed.  The 1H NMR 
spectrum shows the geminal PCU bridge methylene protons resonances at 1.26 and 1.72 ppm 
(d, J = 10.5 Hz) which were assigned to H-4a and H-4s respectively.  From literature,16 it is 
known that this pair of doublets are normally observed in this region with a similar coupling 
constant.  The COSY and NOESY spectra show correlations of H-4a with H-4s as expected.  
H-11a and H-11s (1.04 and 2.10 ppm, d, J = 12.8 Hz) were assigned as above due to the 
relative positions and the size of the coupling constant.  
H-4a and H-4s show both COSY and NOESY correlations with two resonances at 2.15 and 
2.30 ppm, which could be attributed to H-3 or H-5.  The pair of doublets H-11a and H-11s 
also shows both COSY and NOESY correlations with the resonances at 2.47 and 2.75 ppm 
which can be assigned to either H-1 or H-10.  The COSY and NOESY spectra show distinct 
correlation of the protons at 2.30 ppm with a signal at 2.75 ppm; thus confirming that the 
resonance registered at 2.30 and 2.75 ppm are H-3 and H-1 respectively.  The signals at 2.15 
and 2.47 ppm were assigned to H-5 and H-10.  The methine protons (H-5 and H-10) show 
COSY and NOESY correlations to a proton peak at 2.84 ppm which was assigned to H-9.  H-
3 (2.30 ppm) shows both COSY and NOESY correlations with a signal at 2.62 ppm which 
was assigned to H-2.  Also, observed on both COSY and NOESY spectra are the correlation 
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of H-5 (2.15 ppm) with a signal at 2.64 ppm which was assigned to H-6.  A resonance at 3.33 
ppm shows both COSY and NOESY correlations with H-1 (2.75 ppm) and H-6 (2.64 ppm), 
thus this resonance was assigned to H-7.  It is evident from the NOESY spectrum that H-4a 
shows correlations with H-2 and H-6 while H-4s shows correlations with H-9 and H-10.  H-
11s and H-11a show NOESY correlations with H-1 (2.75 ppm) and H-10 (2.47 ppm) while 
H-11a shows an extra NOESY correlation with H-3 (2.30 ppm).  The HSQC spectrum was 
used to further confirm the assignments of the proton and carbon signals of the “cage” 












Table 3: 1H and 13C NMR dataa of PCU-3 side chain 
PCU-3 
Atom δ1Hb J(Hz) δ13Cb 
1 2.75  35.5 
2 2.62  41.4 
3 2.30  46.7 
4a 1.26 10.5 33.7 
4s 1.72 10.5 33.7 
5 2.15  43.0 
6 2.64  41.4 
7 3.33  38.5 
8 -  65.8 
9 2.84  47.5 
10 2.47  42.5 
11a 1.04 12.8 28.1 
11s 2.10 12.8 28.1 
                                         a 600MHz for 1H and 150MHz for 13C.  
                                         b Solvent CD3OD.  
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Using the APT 13C NMR, a methylene signal registering at 24.2 ppm was observed.  This 
carbon shows a HSQC interaction with two proton resonances at 1.36 and 1.19 ppm were 
assigned to Ile-4 Hγ (CH2); the peptide has only the one methylene group apart from the two 
PCY methylene groups.  The proton-split experienced by Ile-4 Hγ (CH2) is the result of the 
interaction with the chiral carbon Cβ to which the Ile-4 Cγ (CH2) is attached.  This effect is 
due to the diastereotopic nature of the two Hγ protons.  Ile-4 Hγ (CH2) shows a COSY 
correlation to the methyl protons at 0.92 ppm and a signal at 1.84 ppm which were assigned 
to Ile-4 3Hδ and Ile-4 Hβ respectively.  Ile-4 Hβ shows a COSY correlation to a methyl signal 
registering at 0.95 ppm, which was assigned to Ile-4 Hγ (CH3).  The signal at 4.19 ppm shows 
COSY correlation to Ile-4 Hβ and was assigned to Ile-4 Hα.  This assignment was further 
confirmed through HMBC correlation between Ile-4 Cα (59.1ppm) and Ile-4 Hγ (CH3) at 
0.95ppm. 
Using the APT 13C NMR and HSQC spectra two methyl proton signals at 0.96 and 0.98 ppm 
show was observed exhibiting a HMBC correlation to the carbon atoms of each other.  The 
only groups that can exhibit such a HMBC correlations are the 2 x Val-2 CH3γ groups (the 
3Hγ at 0.98 ppm correlates with Cγ at16.89 ppm while the other 3Hγ at 0.96ppm correlates 
with the Cγ at 18.7ppm).  These two methyl groups show a COSY correlation to a signal at 
2.13 ppm which was attributed to Val-2 Hβ.  The former protons show a COSY correlation to 
a peak at 4.13 ppm overlapping with Ile-4 Hα; these protons were assigned to Val-2 Hα.  The 
HSQC spectrum was used to assign the remaining proton and carbon signals Val-2 and Ile-4.  
A methyl signal registering at 16.7 ppm was observed in the APT 13C NMR spectrum.  This 
methyl groups shows a HSQC correlation to a doublet peak at 1.47 ppm which was assigned 
to Ala-1 Hβ.  Ala-1 Hβ shows a COSY correlation with a resonance registering at 3.94 ppm 
which was assigned to Ala-1 Hα.  HSQC was used to assign the remaining proton and carbon 
signals for Ala-1. 
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Table 4: 1H and 13C NMR dataa of Ala-1, Val-2 and Ile-4 
Amino 
acid 
δ1Hαb  δ13Cαb δ1Hβb δ13Cβb δ1Hγb δ13Cγb δ1Hδb δ13Cδb 
Ala-1 3.94 49.2 1.47 16.7 - - - - 











a 600MHz for 1H and 150MHz for 13C 
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Attempts to synthesis the polycyclic cage hydantoin derivatives 51 and 52 as anticonvulsant 
agents were unsuccessful.  The poor stability of the novel PCU hydantoin derivatives 56 and 
58 and the adamantane hydantoin derivatives 55 and 57 were the reason for these failed 
attempts.   
PCU hydantoin was successfully hydrolysed to the PCU amino acid 41 and was successfully 
incorporated into the hepta-peptide 108 using a SPPS microwave peptide synthesiser.  The 
peptide was obtained in relatively good yield (53%) and suitably pure for two dimensional 
NMR analysis.  The NMR elucidation was only partially possible for the alanine segments 
due to massive overlap of proton and carbon signals.  The PCU segment was successfully 
identified from the 2D NMR spectra.  Attempt to determine the 3D structure of 108 were 
done through NOESY spectra at -500C.  Unfortunately there were no guide correlations that 
could confirm the β-turn in 108.  Several attempts to obtain a suitable crystal for X-ray 
analysis also met with no success.   
Incorporation of the PCU amino acid 41 into the semantic peptide backbone AVPI as a 
potential anticancer agent was successful.  The target peptide 109 was purified and analysed 
with NMR and MS.  This peptide is currently undergoing biological evaluation at the School 





Melting points were recorded using a Gallenkams melting point instrument.  All melting 
points are uncorrected.  NMR data were recorded on a Bruker ANANCE III 400 MHz 
spectrophotometer while the two dimensional NMR spectra were recorded on a Bruker 
ANANCE III 600 MHz spectrophotometer.  The peptides sequences were synthesised via 
CEM Liberty automated peptide synthesizer instrument and the mass spectra were carried out 
on a Bruker miro TOF-Q II instrument.  Purification was done via semi-prep HPLC on a 
Young Lin Acme 9000 instrument.  The column and solvent conditions are provided below 
where applicable.  Infrared spectra were obtained on a Perkin Elmer spectrum 100 instrument 
with an attenuated total reflection attachment.    
Synthesis of pentacyclo[5.4.0.0.2,6.03,10.05,9]undecane-8-11-dione 73.1 
Freshly cracked cyclopentadiene 69 (76 g 1.12 mol) was added to a stirred solution of p-
benzoquinone 70 (110 g 1.02 mol) in toluene (2000 ml) at 00C and left overnight.  The 
solution was transferred to an evaporating dish and placed in a dark fume hood, the crude 
adduct was thereafter recrystallised from petroleum ether (40-60 0C) resulting in greenish 
yellow crystals.  A solution of adduct 72 in ethyl acetate (5000 ml) was placed directly under 
sun light until the yellow solution turned clear, which is an indication of the completion of 
the reaction.  The solvent was evaporated under reduced pressure and the crude product was 
purified via silica gel column chromatography (ethyl acetate: hexane 40:60, Rf = 20) to afford 
the product 73 as a white powder (110 g, 88%, mp = 2400C). 
The NMR spectra were identical to an authentic sample. 
Synthesis of pentacyclo[5.4.0.0.2,6.03,10.05,9]undecane-8-11-dione-mono-ethylene ketal 
79.2,3 
A mixture of PCU dione 73 (10 g, 0.057 mol), ethylene glycol 78 (4.5 ml, 0.080 mol) and p-
toluenesulfonic acid (0.33 g, 0.19 x 10-2 mol) was dissolved in toluene (45 ml) and refluxed 
using a Dean-Stark apparatus for three days.  The reaction mixture was allowed to cool down 
followed by addition of a cold aqueous solution of 10% Na2CO3 (60 ml) and extracted with 
DCM (3x25 ml); the organic layer was dried using anhydrous Na2SO4.  Filtration of Na2SO4 
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was carried out and the solvent was evaporated in vacuo.  The crude product was purified via 
silica gel column chromatography (40:60 ethyl acetate : hexane, Rf = 0.55) and obtained as a 
white solid (10.3 g, 80%, mp = 710C).  
The NMR spectra were identical to an authentic sample. 
Synthesis of 11-hydroxy-pentacyclo[5.4.0.02,6.03,10.05,9] undecane-8-one-ethylene ketal 
87.2,3 
An ethanolic solution of sodium borohydride 89 (1.75 g in 50 ml) was added over five 
minutes to a stirred solution of PCU monoketal 79 (5 g 2.3 x 10-2mol) in ethanol (50 ml). The 
reaction vessel was placed in an ice bath.  The reaction was stirred for two hours in the ice 
bath and for another two hours at room temperature.  Completion of reduction was monitored 
via TLC technique (ethyl acetate:hexane 40:60, Rf = 0.53).  The mixture was diluted with 
deionised water (50 ml) and extracted with DCM (3 x 40 ml); the organic layer was 
evaporated in vacuo the product was obtained as a white solid (4.6 g, 90%, mp = 2450C). 
The NMR spectra were identical to an authentic sample. 
Synthesis of 11-hydroxy-pentacyclo[5.4.0.02,6.03,10.05,9] undecane-8-one 88.3 
The hydroxy ketal 87 (22.5 g 0.10 mol) was kept in an ice bath; 10 (v/v) of HCl (100 ml) was 
added cautiously and the reaction mixture was allowed to return to room temperature and 
stirred for 18 hours.  The aqueous solution was extracted with DCM (2 x 40 ml) and the 
organic layer was evaporated in vacuo leaving a brown powder.  Purification was achieved 
through silica gel column chromatography (ethyl acetate:hexane 40:60, Rf = 0.37). (16.1 g, 
89.8%, mp = 2550C). 
The NMR spectra were identical to an authentic sample  
Synthesis of Pentacyclo [5.4.0.02,6.03,10.05,9] undecane-8-ol 94.3,4 
A mixture of hydroxy ketone 88 (9 g 0.05 mol) and hydrazine hydrate 96 (21 ml 0.67 mol) in 
ethylene glycol (130 ml) was refluxed at 1200C for six hours.  The reaction mixture was 
allowed to cool to 800C.  At this stage excess KOH (15 g) was added cautiously.  The 
reaction mixture was distilled until the temperature reached 1850C in order to remove the 
excess of hydrazine hydrate and water.  The reaction mixture was refluxed for another three 
hours at 1850C.  The mixture was cooled, followed by dilution with deionised water (150 ml) 
and extracted with DCM (3x100 ml).  The organic layer was removed in vacuo and the crude 
product was purified via steam distillation giving compound 94 as a white power with a 
distinct camphor odour (ethyl acetate:hexane 40:60, Rf = 0.74) (6.8 g 83%, mp = 2280C). 
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The NMR spectra were identical to an authentic sample.  
Synthesis of Pentacyclo [5.4.0.02,6.03,10.05,9] undecane-8-one 64.3,4 
A solution of PCU alcohol 94 (5 g 0.03 mol) in ethyl acetate (35 ml) was added drop wise to 
a stirred mixture of chromium trioxide 101 (6.7 g 6.7x10-2 mol), water (11 ml) and acetic acid 
(110 ml) and the mixture was maintained at 900C overnight.  The reaction mixture turned 
gradually from the dark brown to a green colour which was an evident of the reduction of 
Cr+6 to Cr+3 (Jone’s oxidation).  The reaction mixture was cooled and diluted with deionised 
water (350 ml) followed by extraction with DCM (3 x 100 ml).  The organic layer was 
collected and washed with a saturated solution of NaHCO3 (3 x 100 ml), water (150 ml) and 
dried using anhydrous Na2SO4.  The solvent was removed in vacuo and the product 64 was 
isolated as a white powder (ethyl acetate:hexane 40:60, Rf = 0.78) (3.8 g, 77%, mp = 1650C).   
The NMR spectra were identical to an authentic sample  
Synthesis of PCU hydantoin 60.5,6 
A mixture of monoketone 64 (1g, 0.62x10-2 mol), sodium cyanide (1g 2.04x10-2 mol), 
ammonium carbonate (2g 2.08x10-2 mol), ethanol (10 ml) and ammonia solution (15 ml) was 
sealed in glass pressure vessel and placed in an oil bath at 600C for two hours, 1000C for 
another two hours and at 1200C overnight.  The reaction mixture was allowed to cool and 
added to deionised water (100 ml) followed by extraction with ethyl acetate (150 ml).  The 
organic layer was washed extensively with water and evaporated in vacuo to obtain the 
product as white crystals (ethyl acetate:hexane 50:50, Rf = 0.29) (0.9 g 63%, mp = 2270C).    
The NMR spectra were identical to an authentic sample. 
Synthesis of compound 58 (novel compound).  
A mixture of PCU hydantoin 60 (0.5g, 0.21 x 10-2 mol), 34% formaldehyde 62 (2 ml) and 
K2CO3 (0.05 g 3.6x10-4 mol) was dissolved in isopropanol (8 ml) and stirred for five hours at 
600C.  Deionized water (20 ml) was added to the mixture and extracted with DCM (2 x 25 
ml).  The organic layer was evaporated in vacuo and the crude product was recrystallized 
from ethyl acetate yielding 58 as a white powder (ethyl acetate:hexane 50:50, Rf = 0.20) (0.4 
g 70%, mp = 197-1990C).  IR vmax 3375.74 cm-1, 2936 cm-1, 1768.77 cm-1, 1714 cm-1.  1H 
NMR [(CD3)2SO2, 400MHz]: δH 1.05 (AB, JAB 13.5Hz, 1H), δH 1.16 (AB, JAB 10.3Hz, 1H), 
δH 1.58 (AB, JAB 10.3Hz, 1H), δH 1.85 (AB, JAB 13.5Hz, 1H), δH 2.22 (m, 2H), δH 2.43 (m, 
2H), δH 2.63 (m, 2H), δH 2.74 (s, 1H), δH 2.91 (s, 1H), δH 4.68 (d, 2H), δH 7.91 (s, 1H 
deuterium exchangeable).  13C NMR [(CD3)2SO2, 100MHz]: δC 28.3 (t), δC 33.8 (t), δC 35.3 
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(d), δC 41.1(d), δC 41.4 (d), δC 42.0(d), δC 42.5(d), δC 42.5 (d), δC 48.0 (d), δC 60.3 (d), δC 67.3 
(s), δC 67.3 (t), δC 156.2 (s), δC 176.5 (s). 
Synthesis of compound 56 (novel compound). 
A solution of compound 58 (0.5g, 0.19 x 10-2 mol), triethylamine (3 ml, 2.1 x 10-2 mol) and p-
toluensulfonyl chloride 63 (0.6 g, 0.31 x 10-2 mol) in THF (15 ml) was stirred overnight at 
room temperature.  The reaction mixture was refrigerated for four hours.  A white precipitate 
formed which was filtered and recrystallised from THF providing compound 56 as a white 
powder (0.5 g, 63%, mp = 860C) (chloroform:methanol 95:5, Rf=0.28,).  IR vmax 2951.13 cm-
1, 1781.33 cm-1, 1723.90 cm-1, 680.39 cm-1, 564.21. cm-1.  1H NMR [(CD3)2SO2, 400MHz] δH 
1H NMR [(CD3)2SO2, 400MHz]: δH 1.1 (AB, JAB 12Hz, 1H), δH 1.6 (d, 1H), δH 1.90 (AB, JAB 
12Hz, 1H), δH 2.28 (s, 3H), δH 2.45 (m, 2H), δH 2.60 (m, 2H), δH 2.74 (m, 1H), δH 2.77 (m, 
1H), δH 4.66 (s, 2H), δH 7.13 (d, 2H), δH 7.49 (d, 2H), δH 8.44 (s, 1H deuterium 
exchangeable).  13C NMR [(CD3)2SO2, 100MHz] δC 20.7 (q), δC 28.1 (t), δC 33.8 (t), δC 38.8 
(d), δC 47.9 (d), δC 41.2 (d), δC 41.8 (d), δC 46.0 (d), δC 41.8 (d), δC 47.9(d), δC 57.9 (t), δC 79.2 
(s), δC 125.4 (d), δC 128.0 (d), δC 137.6 (s), δC 145 2(s), δC 155.4 (s), δC 177.7 (s). 
Synthesis of adamantane hydantoin 59. 
A mixture of 2-adamantanone 61 (1 g 0.66 x 10-2 mol), sodium cyanide (1 g 2.04x10-2 mol), 
ammonium carbonate (2 g 2.08x10-2 mol), ethanol (10 ml) and ammonia solution (15 ml) was 
sealed in a glass pressure vessel and placed in an oil bath at 600C for two hours, 1000C for 
two hours and 1200C overnight.  The mixture was allowed to cool and the crude product was 
obtained as a brown precipitate which was filtered and recrystallised from isopropanol 
yielding compound 59 as white crystals (1.3 g, 89%, mp = 3010C).  1H NMR [(CD3)2SO2, 
400MHz] : δH 1.54 (m, 4H), δH 1.67 (s, 2H), δH 1.76(m, 2H), δH 2.0 (d, 2H), δH 8.38 (s, 1H 
deuterium exchangeable), δH 10.48 (s, 1H deuterium exchangeable).  13C NMR [(CD3)2SO2, 
100MHz]: δC 25.6 (d), 26.2 (d), 31.5 (t), 32.8 (t), 34.6 (d), 37.3 (t), 65.5 (s), 155.8 (s), 
177.2(s).   
Synthesis of compound 57 (novel compound). 
A suspension of adamantane hydantoin 59 (1 g 0.45 x1 0-2 mol), 37% formaldehyde 62 (4 ml) 
and K2CO3 (0.1 g 7.2 x 10-4 mol) was stirred overnight in isopropanol (15 ml) at 60 0C.  The 
product was obtained as white precipitate which was filtered and washed extensively with 
water and dried  (chloroform:methanol 90:10, Rf = 0.41) (1.1 g 91%, mp = 118-1200C).  IR 
vmax 3371.6 cm-1, 2894.56 cm-1, 1763.5 cm-1, 1707.8 cm-1.  1H NMR [(CD3)2SO2, 400MHz]: 
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δH 1.56 (m, 4H), δH 1.69 (s, 2H), δH 1.73 (m, 2H), δH 1.77 (m, 1H), δH 1.82 (m, 1H), δH 2.04 
(d, 2H), δH 2.55(d, 2H), δH 4.70 (s, 2H), δH 8.71 (s, 1H deuterium exchangeable).  13C NMR 
[(CD3)2SO2, 100MHz]:  δC 25.5(d), δC 26.2(d), δC 31.5(t), δC 32.7 (t), δC 34.4 (d), δC 37.2 (t), 
δC 60.2 (t), δC 64.4 (s), δC 154.7 (s), δC 174.9 (s). 
Synthesis of compound 55 (novel compound). 
A suspension of compound 57 (0.8 g 0.32 x 10-2 mol), triethylamine (5 ml 3.6x10-2 mol) and 
p-toluenesulfonyl chloride 63 (0.9 g 0.47x10-2 mol) was stirred overnight in THF (30 ml) at 
room temperature.  The precipitate was filtered and washed extensively with THF and the 
white product was dried in vacuo (chloroform:methanol 95:5, Rf = 0.26) (0.9 g 73%, mp = 
1100C).  IR vmax 2901.6 cm-1, 1772.9 cm-1, 1719.1 cm-1, 679.5 cm-1564.3 cm-1.  1H NMR 
[(CD3)2SO2, 400MHz]: δH 1.62 (m, 4H), δH 1.70 (s, 2H), δH 1.79-1.82 (m, 2H), δH 2.00-2.08 
(m, 4H), δH 2.28 (s, 3H), δH 2.42-2.44 (d, 2H), δH 4.70 (s, 2H), δH 7.12 (d, 2H), δH 7.48 (d, 
2H), δH 9.22 (s, 1H deuterium exchangeable).  13C NMR [(CD3)2SO2, 100MHz]: δC 20.7 (q), 
δC 25.4 (d), δC 26.0 (d), δC 31.6 (t), δC 32.4 (t), δC 33.9 (d), δC 37.1 (t), δC 58.1 (t), δC 65.2 (s), 
δC 125.4 (d), δC 128.0 (d), δC 137.6 (s), δC 145.6 (s), δC 153.9 (s), δC 176.0 (s).  
Synthesis of compound 66 (novel compound). 
To an ice bath cooled mixture of 48% HBr (1.5 ml) and compound 57 (0.5 g 0.20x10-2 mol) 
was added concentrated H2SO4 (0.5 ml) cautiously.  After that the mixture was stirred at 600C 
for five hrs.  The precipitate was filtered followed by thorough washing with water (50 ml) 
and 10 % ammonia solution (20 ml).  The crude product was recrystallised from THF and 
gave compound 66 as a white powder (DCM:methanol 90:10, Rf = 0.33) (0.78 g, 62%, mp = 
263-2650C).  IR vmax 3379.8 cm-1, 2895 cm-1.01, 1779.83 cm-1, 1714.09 cm-1, 1433.3 cm-1, 
609.5 cm-1.  δH 1.56 (m, 4H), δH 1.69 (s, 2H), δH 1.73 (m, 2H), δH 1.77 (m, 1H), δH 1.82 (m, 
1H), δH 2.04 (d, 2H), δH 2.55(d, 2H), δH 4.70 (s, 2H), δH 8.72 (s, 1H deuterium exchangeable).  
13C NMR [(CD3)2SO2, 100MHz]:  δC 25.5(d), δC 26.2(d), δC 31.5(t), δC 32.7 (t), δC 34.4 (d), 
δC 37.2 (t), δC 60.2 (t), δC 64.4 (s), δC 154.7 (s), δC 174.9 (s). 
Attempted synthesis of compounds 53 and 54.  
Attempt A: A solution of compound 64 (0.44 g 0.16 x 10-2 mol) in DCM (3 ml) was added 
drop wise to a stirred solution of (a) compound 55 (0.25 g 0.06 x 10-2 mol) (b) compound 56 
(0.25 g 0.06 x 10-2 mol) and triethylamine (0.4 ml 0.3 x 10-2 mol) in DCM (10 ml) and the 
mixture was stirred overnight at room temperature.  There was no evidence of product 
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formation when the reaction was monitored using NMR and LCMS.  This was also the result 
after the reaction was refluxed for 24 hours.   
Attempt B: A solution of (a) compound 55 (0.1 g 0.02 x 10-2 mol) (b) compound 56 (0.1 g 
0.02x10-2 mol) in acetonitrile (2 ml) was added drop wise to a stirred solution of compound 
64 (0.15 g 0.05 x 10-2 mol) and triethylamine (0.35 ml 0.25 x 10-2 mol) in acetonitrile (8 ml).  
The solution was then stirred overnight at ambient temperature.  There was no evidence of 
product formation when the reaction was monitored with NMR and LCMS.  This was also 
the result after the reaction was refluxed for 24 hours. 
Attempt C: A suspension of (a) compound 55 (0.1 g 0.02 x 10-2 mol) (b) compound 56 (0.1 g 
0.02 x 10-2 mol) in THF (3.5 ml) was added drop wise to a stirred solution of compound 64 
(0.15 g 0.05 x 10-2 mol) and sodium hydride (0.1 g 0.25 x 10-2mol) in THF (8 ml) under inert 
atmosphere. The mixture was stirred over night at ambient temperature.  The precipitate was 
filtered and the filtrate was dried in vacuo.  There was no evidence of product formation 
when the filtrate and precipitate were analysed with NMR and LCMS.  This was also the 
result after the reaction was refluxed for 24 hours. 
Attempt D A solution of (a) compound 55 (0.1 g 0.02 x 10-2 mol) (b) compound 56 (0.1 g 0.02 
x 10-2mol) in THF (3.5 ml) was added dropwise to a stirred solution of compound 64 (0.15 g 
0.05 x 10-2 mol) and sodium hydroxide (0.1 g 0.25 x 10-2 mol) in THF (13 ml).  The reaction 
mixture was stirred over night at ambient temperature.  There was no evidence of product 
formation when the filtrate and precipitate were analysed with NMR and LCMS.  This was 
also the result after the reaction was refluxed for 24 hours. 
Attempt E A solution of compound 64 (0.3 g 0.1 x 10-2 mol) in DCM (3 ml) was added drop 
wise to a stirred solution of compound 65 (0.12 g 0.04 x 10-2 mol) and sodium hydroxide 
(0.15 g 0.37 x 10-2 mol) in DCM (6 ml), the reaction was stirred for 12 hrs at 500C.  There 
was no evidence of product formation when the filtrate and precipitate were analysed with 
NMR and LCMS.  This was also the result after the reaction was refluxed for 12 hours. 
Attempted synthesis of compound 66. 
Concentrated H2SO4 (0.5 ml) was added cautiously to an ice bath cooled solution of 
compound 58 (0.5 g 0.20 x 10-2 mol) in 48% HBr (1.5 ml) and the mixture was stirred at 600C 
for 5 hrs.  The precipitate was filtered followed by thorough washing with water (3 x 50 ml) 
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and 10 % ammonia solution (3x20 ml).  The only observable product was PCU hydantoin 60 
(using NMR and TLC analysis). 
Attempted synthesis of compounds 51 and 52. 
A solution of (a) compound 57 (0.4 g 0.16 x 10-2 mol) (b) compound 58 (0.4 g 0.16x10-2 mol) 
in acetonitrile (5 ml) was added drop wise to a solution of phosphorus chloride oxide 67 (0.25 
g 0.16x10-2 mol) and pyridine (1 ml 1x10-2 mol) in acetonitrile (10 ml).  The reaction mixture 
was stirred for 5 hrs at 00C and thereafter adjusted to pH 1 via addition of 10 % aqueous HCl 
and stirred at room temperature for another 1 hour.  Deionised water (20 ml) was added to the 
mixture and the product was extracted with ethyl acetate (3 x 25 ml).  The organic layer was 
dried and there was no evidence of product formation. 
Synthesis of Fmoc PCU amino acid 106.6 
A suspension of PCU hydantoin 60 (1.0 g, 4.3 x 10-3 mol) in NaOH (1.25 M, 50 ml) was 
sealed in a pressure reactor vessel and heated in an oil bath at 1700C for 12 hours.  The 
reaction mixture was cooled and adjusted to pH 9 by addition of concentrated HCl.  The 
mixture was added slowly to a stirred solution of 9-flourenylmethyl chloroformate 105 (1.7 g, 
0.6x10-2 mol) in dioxan (20 ml) and stirred at ambient temperature overnight.  The reaction 
mixture was acidified to pH 2 via addition of HCl (37%) and extracted with ethyl acetate 
(2x100 ml).  The organic layer was evaporated and the crude product was purified via silica 
gel column chromatography (choloroform:methanol:acetic acid 95:4:1, Rf = 0.42) giving the 
product 106 as a white powder (1.3 g, 73%, mp = 216 0C).  
The NMR spectra were identical to an authentic sample. 
General procedure for the synthesis of peptides using microwave power. 
Solutions of required amino acids (0.2 x 10-3 mol), N,N-diisopropylethylamine (DIPEA) 
(1x10-3 mol) and hydroxybenzotriazole (HOBt) (2 x 10-3 mol) in DMF were made up and 
fitted in the appropriate reaction vessels on the automatic peptide synthesizer.  All peptides 
were synthesized on a 0.1 x 10-3 mol scale using microwave power.  The details of the 





Table 5: details of the microwave conditions for synthesis of peptide 106 and 107  
 Microwave power/W Time/s Temperature/°C 
Arg Coupling  0 1500 156.1 
25 300 
Normal Coupling 25 300 71 
Deprotection 60 180 71 
An arginine coupling method was used for coupling the PCU amino acid (i) to each of (i-1) 
and (i+1)***  The normal coupling method was used for subsequent couplings and for Fmoc 
deprotection, the deprotection method was used as indicated in table. 
Cleavage of peptides from rink amide resin. 
The rink amide resin bound peptide was washed with DCM (3 x 10 ml) in a manual peptide 
synthesis reaction vessel.  The resin was dried and the cleavage mixture (10 ml) of 2.5% (v/v) 
(TIS), 2.5% (v/v) water and 95% (v/v) TFA was added to the resin and stirred for 1 hour.  
The resin was filtered and washed with methanol (30 ml).  TFA was removed via bubbling 
air through the mixture and the crude peptide was precipitated with cold ether.  
General Procedure for preparative HPLC purification of novel compounds. 
A solvent system containing acetonitrile (solvent B) and water (Solvent A) was used for 
HPLC analysis of compounds.  A ACE 5 C18 150x21.2 mm column was used.  Gradient 
elution system of 5% (Solution B) and 95% (Solution A) was used initially and this was 
changed linearly over 60 minutes to 95% (Solution B) and 5% (Solution A) at 17.00 ml per 
minute. 
Data for Novel peptides. 
H2N-(Ala)3-PCU-(Ala)2-Ala-Fmoc 106a and 106b. 
Yield: 35% and 18%. LC-MS Retention time: 11.4 and 12.2 min. ESI-MS 880 [M + 23(Na) + 
4 (4D+)] m/z.  NMR data provided in Tables 1 and 2. 
                                                 
*** (i-1) and (i+1) are Ala and Ala in case of Ala3-PCU-Ala-2-Ala-Fmoc sequence  and Val and Ile respectively 




Ala-Val-PCU-Ile 107a and 107b. 
Yield: 27% and 23%. LC-MS Retention time: 6.2 and 7.3 min. ESI-MS m/z 488.4 [M + 1] 
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Spectrum 58: ESI Mass spectrum of peptide 109 
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